Seres Therapeutics Inc (NASDAQ:MCRB) — Market Cap & Net Worth
Market Cap & Net Worth: Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc (NASDAQ:MCRB) has a market capitalization of $41.18 Million ($41.18 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22717 globally and #4993 in its home market, demonstrating a -22.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seres Therapeutics Inc's stock price $4.10 by its total outstanding shares 10044781 (10.04 Million). Also see MCRB total assets for a full breakdown of the balance sheet.
Seres Therapeutics Inc Market Cap History: 2015 to 2026
Seres Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $352.47 Million to $41.18 Million (-17.03% CAGR). Also see cash flow conversion of Seres Therapeutics Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Seres Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #648 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2145 of 3165 |
Weight: Seres Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Seres Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seres Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MCRB share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
189.44x
Seres Therapeutics Inc's market cap is 189.44 times its annual revenue
Latest Price to Earnings (P/E) Ratio
26.24x
Seres Therapeutics Inc's market cap is 26.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $99.44 Million | $21.77 Million | -$91.58 Million | 4.57x | N/A |
| 2017 | $101.85 Million | $32.10 Million | -$89.38 Million | 3.17x | N/A |
| 2018 | $45.40 Million | $28.27 Million | -$98.94 Million | 1.61x | N/A |
| 2019 | $34.65 Million | $34.51 Million | -$70.28 Million | 1.00x | N/A |
| 2020 | $246.10 Million | $33.22 Million | -$89.13 Million | 7.41x | N/A |
| 2021 | $83.67 Million | $144.93 Million | -$65.58 Million | 0.58x | N/A |
| 2022 | $56.25 Million | $7.13 Million | -$250.16 Million | 7.89x | N/A |
| 2023 | $14.06 Million | $126.33 Million | -$113.72 Million | 0.11x | N/A |
| 2025 | $149.47 Million | $789.00K | $5.70 Million | 189.44x | 26.24x |
Competitor Companies of MCRB by Market Capitalization
Companies near Seres Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Seres Therapeutics Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Seres Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Seres Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Seres Therapeutics Inc's market cap moved from $352.47 Million to $ 41.18 Million, with a yearly change of -17.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $41.18 Million | -72.45% |
| 2025 | $149.47 Million | +1690.61% |
| 2024 | $8.35 Million | -40.64% |
| 2023 | $14.06 Million | -75.00% |
| 2022 | $56.25 Million | -32.77% |
| 2021 | $83.67 Million | -66.00% |
| 2020 | $246.10 Million | +610.14% |
| 2019 | $34.65 Million | -23.67% |
| 2018 | $45.40 Million | -55.42% |
| 2017 | $101.85 Million | +2.42% |
| 2016 | $99.44 Million | -71.79% |
| 2015 | $352.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Seres Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.18 Million USD |
| MoneyControl | $41.18 Million USD |
| MarketWatch | $41.18 Million USD |
| marketcap.company | $41.18 Million USD |
| Reuters | $41.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more